Orion Oyj Class A · OMXHEX:ORNAV

Orion Oyj Class A — Q2 2026 Earnings Presentation

62 slides from Orion Oyj Class A's earnings presentation, Jul 17, 2026

  1. Slide 1: Orion Equity story

    Orion Equity story

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of

  3. Slide 3: Orion Pharma is a global pharmaceutical company with decades of expertise in innovation

    Orion Pharma is a global pharmaceutical company with decades of expertise in innovation Our strategy is focused on FINANCIALS 2025 building well-being and growth NET SALES driven by Innovative Medicines, EUR 1,890 million while our diversified and profitable +23% business portfolio provides stable O

  4. Slide 4: Our diverse business portfolio provides both high growth potential and stable cash flows

    Our diverse business portfolio provides both high growth potential and stable cash flows Innovative Generics and Branded Products Animal Health Fermion Medicines Consumer Health Respiratory Companion API Portfolio CNS 300+ products animals & manufacturing highlights Women’s Health livestock & CDMO N

  5. Slide 5: With strong track record in delivering financial results, we are gaining growth momentum

    With strong track record in delivering financial results, we are gaining growth momentum Operating profit Net sales split by geography (FY2025, %) Net sales (EUR million) (EUR million) 2,000 700 1,890 632 16.1% 26.9% 183 600 17.1% 1,542 183 1,500 134 500 29.4% 1,341 1,190 440 417 1,041 234 32 400 1,

  6. Slide 6: How we are building our growth

    How we are building our growth Innovation Geographic expansion Portfolio expansion M&As • Key driver is Innovative • Branded Products is • Branded Products targets in- • Focus on organic Medicines’ pipeline in strengthening its presence in licensing opportunities in all growth oncology and pain Euro

  7. Slide 7: Key partnerships drive short and mid-term growth

    Key partnerships drive short and mid-term growth Nubeqa® (darolutamide) Opevesostat Levosimendan Partner: Partner: Partner: Annually tiered royalty Annually tiered royalty from Annually tiered royalty from Annual average now ~25% low double-digit to low high single digit to low twenties teens Launch

  8. Slide 8: Branded Products build on innovative legacy products with Easyhaler leading the way

    Branded Products build on innovative legacy products with Easyhaler® leading the way 5.1% 315 11.0% 288 32 +3x growth 271 177 261 24 over the decade 166 28 21 100 144 93 130 113 94 173 115 117 157 105 15 22 90 89 95 52 77 EUR million 52 EUR million 64 170 183 51 130 146 91 99 2022 2023 2024 2025 H1

  9. Slide 9: Financial objectives

    Financial objectives Strategy period 2024–2028 Net sales Operating profit CAGR ≥8%1 To grow faster than net sales1,2 Equity ratio Return on equity (ROE) ≥50% ≥25% Dividend Annually increasing dividend – payout ratio 50%–100% 1 Base year 2023 9 Investor Presentation © Orion Corporation 2 Without EUR

  10. Slide 10: Key themes for Orion as an investment

    Key themes for Orion as an investment Delivering net sales growth Generating stable cash flow Balanced capital allocation Innovative Medicines business Branded Products, Generics and Orion reinvests in R&D and division drives growth. Nubeqa® Consumer Health, and Animal growth, and targets increasing

  11. Slide 11: Research & Development

    Research & Development 11 Investor Presentation © Orion Corporation

  12. Slide 12: We have a long history of bringing innovative treatments to market

    We have a long history of bringing innovative treatments to market Proprietary human pharmaceuticals developed by Orion 1993 1998 2000 2003 2011 2018 1988 1994 1999 2002 2004 2014 2019 12 Investor Presentation © Orion Corporation

  13. Slide 13: Orion Pharma's key clinical development pipeline

    Orion Pharma’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication Phase I Phase II Phase III ARASTEP (darolutamide) prostate cancer (BCR2) DASL-HiCaP (darolutamide) (Neo-)adjuvant prostate cancer OMAHA-003 (opevesostat) prostate cancer (later-line mCRPC3) OMAHA-004

  14. Slide 14: Estimated timing of clinical trial results

    Estimated timing of clinical trial results Invented by Developer(s) Trial/compound Indication 2026 2027 2028 2029 ARASTEP (darolutamide) prostate cancer (BCR2) DASL-HiCaP (darolutamide) (Neo-)adjuvant prostate cancer OMAHA-003 (opevesostat) prostate cancer (later-line mCRPC3) OMAHA-004 (opevesostat)

  15. Slide 15: Orion's innovations approved and in Phase 3 in different prostate cancer stages

    Orion’s innovations approved and in Phase 3 in different prostate cancer stages Patient progression in prostate cancer (Neo-)Adjuvant Non-metastatic Metastatic early-stage mid-stage late-stage BCR nmCRPC mHSPC mCRPC DASL-HiCaP ARASTEP ARAMIS ARASENS OMAHA-003 darolutamide + LHRHA + darolutamide + AD

  16. Slide 16: Aspirational benefits of ODM-212, a TEAD inhibitor, in patients with cancer

    Aspirational benefits of ODM-212, a TEAD inhibitor, in patients with cancer Monotherapy-TEADES Study TEADCO-Combination Study (ODM-212 has anti-tumour activity) (ODM-212 has resistance-prevention activity) Cancers driven by the Hippo pathway Prevention of cancer treatment resistance Targeting solid

  17. Slide 17: Key milestones reached for ODM-212: a potential best-in-class TEAD inhibitor

    Key milestones reached for ODM-212: a potential best-in-class TEAD inhibitor OPPORTUNITY Targeting Hippo pathway dysregulated tumours • Small molecule oral pan-TEAD inhibitor • Rare cancers with limited treatment options such as mesothelioma and EHE1 PHASE 1 RESULTS TEADES – Phase 1 results announce

  18. Slide 18: We are a trusted innovator in animal health products

    We are a trusted innovator in animal health products Main Orion Animal Health marketing authorisations Kefavet Comforion 1987 1998 2008 2015 2019 2021 1983 1989 2002 2012 2018 2020 Geepenil Benzorion 18 Investor Presentation © Orion Corporation

  19. Slide 19: Strategy and financial targets

    Strategy and financial targets 19 Investor Presentation © Orion Corporation

  20. Slide 20: Building well-being

    Building well-being Inspired by our Nordic heritage, we strive to empower people around the world to live their lives to the fullest – today and tomorrow. Build a customer-driven Expand to new geographies and Develop Inn portfolio strengthen global partnerships growth enablers ov tiv a e a lt h M r

  21. Slide 21: The dream of a truly global Finnish pharma company has existed for a long time – why now?

    The dream of a truly global Finnish pharma company has existed for a long time – why now? Promising R&D capabilities and All of our business areas projections for the quality have been have demonstrated coming decade: validated. resilience by establishing The stellar success of We have excelled in g

  22. Slide 22: Building well-being

    Building well-being Inspired by our Nordic heritage, we strive to empower people around the world to live their lives to the fullest – today and tomorrow. • Innovative Medicines for Oncology and Pain Build a customer- • Brand products for Respiratory, Central Nervous Innovative Branded driven portfo

  23. Slide 23: Our growth will come in three phases

    Our growth will come in three phases STRENGTHEN & BUILD & INVEST ACCELERATE EXPAND Build and invest into Grow & maximize value Strengthen European & global commercial assets of global assets APAC market position and capabilities Inspired by our Nordic heritage, we strive to empower people around the

  24. Slide 24: Financial objectives

    Financial objectives Strategy period 2024–2028 Net sales Operating profit CAGR ≥8%1 To grow faster than net sales1,2 Equity ratio Return on equity (ROE) ≥50% ≥25% Dividend Annually increasing dividend – payout ratio 50%–100% 1 Base year 2023 24 Investor Presentation © Orion Corporation 2 Without EUR

  25. Slide 25: Orion's strategy period 2024–2028 – key takeaways

    Orion’s strategy period 2024–2028 – key takeaways Financial objectives provide us a framework to operate and maintain the right balance between expenditure and profitability Increasing Growing EBIT Growing investments to and annually Enable AND revenues build the future increasing of Orion dividend

  26. Slide 26: Capital allocation focus

    Capital allocation focus In-licensing / Focused Maintaining Internal R&D acquiring External M&As to gain Dividends & increasing pipeline commercial innovation strategic capacity assets competences Higher Lower 26 Investor Presentation © Orion Corporation

  27. Slide 27: Dividend distribution policy and dividend history

    Dividend distribution policy and dividend history • Orion’s dividend distribution takes into account distributable funds and capital expenditure and other financial requirements in medium and long term to achieve the financial objectives. EUR Dividend distribution history 2,00 110% 1,75 100% 0.20 0.

  28. Slide 28: Our Sustainability Agenda

    Our Sustainability Agenda 28 Investor Presentation © Orion Corporation

  29. Slide 29: Orion's Sustainability Agenda

    Orion’s Sustainability Agenda Patient safety as a top priority Active work for a better environment Patient safety has been a priority for us for We want to be the environmental leaders in over a hundred years and it continues to be our industry. Orion is committed to working the cornerstone of our

  30. Slide 30: Orion's climate targets are backed by science

    Orion’s climate targets are backed by science Validation from the Science Based Targets initiative (SBTi) confirms that our near-term emissions reduction targets are in line with the latest climate science 70% 78% Orion commits to reduce absolute scope Orion commits that 78% of its suppliers by emis

  31. Slide 31: Orion Half-Year Financial Report January-June 2026

    Orion Half-Year Financial Report January-June 2026 17 July 2026

  32. Slide 32: Q2 2026 Highlights

    Q2 2026 Highlights • Growth accelerated and profitability improved • Strong growth in Nubeqa® royalties and product sales • Great quarter for Branded Products • Several key milestones reached in the research and development of ODM-212 32 17 July 2026 © Orion Corporation

  33. Slide 33: Q2 2026 Financial highlights

    Q2 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 33.9% (25.1%) +25.2% +68.8% +69.7% 521.6 176.6 1.00 416.5 104.6 0.59 Q2/2025 Q2/2026 Q2/2025 Q2/2026 Q2/2025 Q2/2026 33 17 July 2026 © Orion Corporation

  34. Slide 34: Net sales bridge (MEUR)

    Net sales bridge (MEUR) 521.6 -1.1 -2.9 3.6 0.3 10.3 95.0 416.5 Q2/2025 Innovative Branded Products Generics and Animal Health Fermion Translation Q2/2026 Medicines Consumer Health differences and other operations 34 17 July 2026 © Orion Corporation The figures in the chart are rounded, which is why

  35. Slide 35: Operating profit bridge (MEUR)

    Operating profit bridge (MEUR) -0.1 -4.3 -15.2 176.6 76.6 -2.2 104.6 17.3 Q2/2025 Changes in Changes in prices, Royalties Milestones Other operating Fixed costs Q2/2026 sales volume COGS, product income and mix and FX expenses 35 17 July 2026 © Orion Corporation The figures in the chart are rounded,

  36. Slide 36: H1 2026 Financial highlights

    H1 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 31.0% (23.7%) +21.8% +59.6% +60.2% 939.3 291.3 1.64 771.0 182.5 1.02 H1/2025 H1/2026 H1/2025 H1/2026 H1/2025 H1/2026 36 17 July 2026 © Orion Corporation

  37. Slide 37: Innovative Medicines

    Innovative Medicines +60.3% Nubeqa® sales (MEUR) +64.8% 392.0 237 241.6 10.2 4.8 213 64 48 166 244.5 152 145 146.7 140 12.9 48 6.6 36 44 50 NET SALES MEUR NET SALES MEUR 236.8 381.8 95 92 72 26 165 173 38 140.1 231.6 50 21 116 118 18 96 95 69 51 54 32 2024 2024 2024 2024 2025 2025 2025 2025 2026 202

  38. Slide 38: Branded Products

    Branded Products • Robust growth momentum in +12.8% +9.9% Women’s Health therapy area, 90.7 172.9 driven by Divina® product range 80.4 14.0 157.4 22.2 7.9 15.0 • Easyhaler® budesonide- formoterol contributed 27.7 51.7 significantly to the growth in the 28.2 51.5 respiratory therapy area NET SALES ME

  39. Slide 39: Generics and Consumer Health

    Generics and Consumer Health • Slight decline in generic -0.8% +0.3% prescription drugs net sales and 135.0 133.9 266.7 267.4 slight increase in consumer health 31.1 products net sales 31.9 64.4 66.3 • License agreement with Shilpa to commercialise intravenous (iv) nivolumab biosimilar in Europe NET

  40. Slide 40: Animal Health

    Animal Health • Timing of deliveries impacted -7.9% -2.4% 36.8 72.0 negatively Q2 net sales against 70.2 the strong comparison period 33.9 • In May, Tessie® (tasipimidine oral solution) received approval from the U.S. Food and Drug Administration (FDA). NET SALES MEUR NET SALES MEUR • We expect our

  41. Slide 41: Fermion

    Fermion • Growth is mostly due to timing of +19.9% +17.1% deliveries and it is expected to 21,5 36,8 level out during H2/2026 17,9 31,4 • Water damage at one Fermion plant in Hanko in July during summer maintenance break • Recovery plan in place and NET SALES MEUR NET SALES MEUR implemented • Based

  42. Slide 42: Top 10 products and net sales split in H1 2026

    TOP 10 products and net sales split in H1 2026 EUR vs. Product or product portfolio million 2025 1. Nubeqa® 381.8 +64.9% 4% 7% 2. Easyhaler® product portfolio 95.3 +7.2% 3. Entacapone products1 44.4 -4.0% 4. Divina® series 22.2 +47.6% 42% 5. Dexdomitor®, Domitor®, Domosedan® and Antisedan® 16.9 -12.

  43. Slide 43: Key collaboration agreements

    Key collaboration agreements 43 Investor Presentation © Orion Corporation

  44. Slide 44: Global agreement with Bayer for development and commercialisation of darolutamide (Nubeqa)

    Global agreement with Bayer for development and commercialisation of darolutamide (Nubeqa®) Annually tiered royalties to Orion Milestone payments to Orion Amount Year recorded The average annual royalty rate is currently ~25% Upfront payment EUR 50 million 2014 ✓ Orion manufactures Nubeqa® for globa

  45. Slide 45: Exclusive global license agreement with MSD/Merck

    Exclusive global license agreement with MSD/Merck on opevesostat (ODM-208/MK-5684) and other drugs targeting CYP11A1 Financial terms Key clinical development projects Upfront payment USD 290 million 2022 ✓ Project Phase Indication Trial on Potential milestone payments to Orion total up to USD 1.63 b

  46. Slide 46: Exclusive global license agreement with Tenax

    Exclusive global license agreement with Tenax on levosimendan Financial terms Key clinical development projects Potential milestone payments to Orion total up to USD 61 million Project Phase Indication Trial on Approval / regulatory milestones payments Up to USD 16 million Clinicaltrials Sales miles

  47. Slide 47: Appendices

    Appendices 47 Investor Presentation © Orion Corporation

  48. Slide 48: Outlook for 2026

    Outlook for 2026 (specified on 17 July 2026) Net sales EUR 2,000 million–EUR 2,100 million Operating profit EUR 650 million–EUR 750 million 48 Investor Presentation © Orion Corporation

  49. Slide 49: 92,979 registered shareholders on 30 June 2026

    92,979 registered shareholders on 30 June 2026 By number of shares By number of votes Households (Finnish retail) 4% 2% 4% 6% Non-Finnish holders and 10% nominee-registered 7% Private corporations 6% 37% Public sector 13% Non-profit institutions 60% Financial and insurance 10% corporations 39% 49 In

  50. Slide 50: Largest shareholders by votes and shares on 30 June 2026

    Largest shareholders by votes and shares on 30 June 2026 # Shareholder % of votes # Shareholder % of shares 1 Erkki Etola and companies 6.82% 1 Ilmarinen Mutual Pension Insurance Company 3.34% 2 Maa- ja vesitekniikan tuki r.y. and companies 5.65% 2 Varma Mutual Pension Insurance Company 3.16% 3 Ilma

  51. Slide 51: Orion B share performance

    Share price, EUR 70 25 85 80 75 65 60 55 50 45 40 35 30 20 15 10 30-Jun-26 31-Mar-26 31-Dec-25 30-Sep-25 Orion B share price 30-Jun-25 31-Mar-25 31-Dec-24 30-Sep-24 30-Jun-24 31-Mar-24 31-Dec-23 30-Sep-23 OMXH-portfolio 30-Jun-23 31-Mar-23 31-Dec-22 30-Sep-22 30-Jun-22 31-Mar-22 31-Dec-21 Europe/Pha

  52. Slide 52: Net sales and operating profit by quarter (MEUR)

    Net sales and operating profit by quarter (MEUR) Net sales, EUR million Operating profit, EUR million 695 328 522 245 492 471 418 417 423 434 202 308 355 177 278 290 328 321 284 301 295 271 121 115 105 93 93 78 82 80 71 66 55 56 47 41 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2022 2023 2024 2025 2026 2022 2023 2024 2

  53. Slide 53: Quarterly net sales by business division (MEUR)

    Quarterly net sales by business division (MEUR) Innovative Medicines Branded Products Generics and Consumer Health 397 247 127 242 230 137 135 123 134 142 129 142 145 134 132 134 150 131 134 127 133 136 171 150 157 147 80 60 77 67 80 91 82 76 62 67 72 89 98 73 70 71 69 67 80 73 61 68 54 52 42 39 22

  54. Slide 54: Quarterly net sales by business division (MEUR)

    Quarterly net sales by business division (MEUR) Animal Health Fermion 37 24 35 36 34 35 35 34 34 34 22 32 31 20 30 19 20 20 19 27 27 27 18 18 18 17 17 16 23 15 16 14 14 14 18 13 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2022 2023 2024 2025 2026 54 Investor Presentation © Orion Corporation

  55. Slide 55: Fixed costs (MEUR)

    Fixed costs (MEUR) MEUR Q2/2026 Q2/2025 Change 1–6/2026 1–6/2025 Change Sales and marketing -75.0 -71.9 +4.2% -147.5 -135.4 +8.9% Research and development -62.2 -49.1 +26.7% -110.4 -90.0 +22.7% Administrative -23.9 -24.8 -3.6% -43.3 -43.3 -4.9% 100 80 60 40 20 0 Sales and marketing Research and deve

  56. Slide 56: Key financial figures

    Key financial figures 2022 2023 2024 2025 1-6/2026 Change % Net sales, EUR million 1,340.6 1,189.7 1,542.4 1,889.5 939.3 +21.8% EBITDA, EUR million 487.1 326.4 509.4 688.3 322.3 +53.3% % of net sales 36.3% 27.4% 33.0% 36.4% 34.3% Operating profit, EUR million 439.6 274.9 416.6 631.6 291.3 +59.6% % o

  57. Slide 57: Income statement

    Income statement EUR million 2022 2023 2024 2025 1-6/2026 Change % Net sales 1,340.6 1,189.7 1,542.4 1,889.5 939.3 +21.8% Cost of goods sold -489.0 -531.9 -596.0 -676.5 -345.4 +7.6% Gross profit 851.6 657.7 946.4 1,213.0 593.9 +31.9% Other operating income and expenses 5.7 43.7 9.5 5.4 -1.3 <-100% S

  58. Slide 58: Royalties and milestones

    Royalties and milestones Additional info on milestones 2014 includes significant part of EUR 50 million darolutamide collaboration signing fee from Bayer 2019 includes EUR 45 million milestone from Bayer for the first commercial sales of darolutamide in the USA 620 2020 includes EUR 28 million miles

  59. Slide 59: Financial position

    Financial position ASSETS EQUITY AND LIABILITIES EUR million 6/26 6/25 Change % 12/25 EUR million 6/26 6/25 Change % 12/25 Property, plant and equipment 464.33 431.22 +7.7% 457.4 Share capital 92.2 92.2 92.2 Other reserves 3.2 5.4 -40.6% 2.9 Goodwill 87.19 87.19 87.2 Cumulative translation adjustmen

  60. Slide 60: Development of capital expenditure (MEUR)

    Development of capital expenditure (MEUR) 220 200 180 160 VMD (Inovet) acquisition 101 Depreciation, amortisation and impairment 140 Intangible assets 120 Property, plant and equipment 4 100 22 80 51 20 8 9 23 34 60 5 29 24 7 6 91 40 35 19 5 7 12 6 8 70 67 72 64 15 52 52 59 20 40 39 45 38 35 37 34 2

  61. Slide 61: Development of net working capital

    Development of net working capital % of net sales EUR million 50% 40% 1000 900 30% 800 700 20% 600 500 10% 400 300 0% 200 -10% 100 0 -20% -100 -200 -30% -300 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec2

  62. Slide 62: Upcoming events

    Upcoming events Interim Report 1–9/2026 28/10/2026 Financial Statement Release 2026 17/2/2027 AGM planned to be held 23/3/2027 Interim Report 1–3/2027 22/4/2027 Half-Year Financial Report 1–6/2027 20/7/2027 Interim Report 1–9/2027 27/10/2027 62 Investor Presentation © Orion Corporation

Orion — Q2 2026 Earnings Presentation on 6ix